C-OODUmitochondrial uncoupling, Controlled Metabolic Accelerators, oral medicines
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Rivus Pharmaceuticals mitochondrial uncoupling, Controlled Metabolic Accelerators, oral medicines
Rivus Pharmaceuticals is focused on advancing cardiometabolic health by developing new oral medicines from its proprietary development platform. Its lead therapy HU6 is an oral MASH therapy in the ongoing AMPLIFY Phase 2 trial. Its pipeline also includes RV-8451, a muscle-preserving oral GLP-1 in IND-enabling studies for obesity.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Rivus Pharmaceuticals — Translational · Bottom quartile. Derived deterministically from 3 extracted project(s). Most-advanced status: phase 2. Band: translational. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic